MAGEB2抗体;MAGEB2 Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P11919(MAGEB2 Antibody) at dilution 1/35. (Original magnification: ×200)    

  
  

The MAGEB2 antibody targets the melanoma-associated antigen B2 (MAGEB2), a member of the MAGE (melanoma-associated antigen) gene family. MAGE proteins are classified as cancer-testis (CT) antigens due to their restricted expression in normal tissues (primarily testis and placenta) and frequent reactivation in various cancers. MAGEB2. located on the X chromosome, is implicated in tumorigenesis, though its exact biological function remains under investigation. It is thought to regulate transcription or cell cycle progression via interactions with E3 ubiquitin ligases or chromatin modifiers.

Antibodies against MAGEB2 are essential tools for studying its expression patterns, subcellular localization, and interactions in both physiological and pathological contexts. In research, these antibodies are used in techniques like immunohistochemistry, Western blotting, and immunofluorescence to detect MAGEB2 overexpression in cancers such as melanoma, lung, and bladder carcinomas. Clinically, MAGEB2 is explored as a potential biomarker for cancer diagnosis or prognosis, and its immunogenic properties make it a candidate target for immunotherapy, including CAR-T cells or vaccines. However, challenges persist due to its low immunogenicity in vivo and potential off-target effects. Studies using MAGEB2 antibodies continue to clarify its role in cancer biology and therapeutic targeting.